A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer

BACKGROUND: Epidermal growth factor receptor (EGFR) is overexpressed in pancreatic cancer. EGFR expression plays a potentially important role in modulation of tumor sensitivity to either chemotherapy or radiotherapy. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR/HER1. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanghvi, Samrat M., Coffman, Alex R., Hsueh, Chung-Tsen, Kang, Joseph, Park, Annie, Solomon, Naveenraj L., Garberoglio, Carlos A., Reeves, Mark E., Slater, Jerry D., Yang, Gary Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459205/
https://www.ncbi.nlm.nih.gov/pubmed/36092320
http://dx.doi.org/10.21037/jgo-22-327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459205/
https://www.ncbi.nlm.nih.gov/pubmed/36092320
http://dx.doi.org/10.21037/jgo-22-327

Ejemplares similares